A major trial finds the beta blocker bisoprolol neither improves nor worsens outcomes in people with COPD, despite the cardiovascular risk.
Imagine someone you care about suddenly experiencing chest pain, turning pale, and breathing heavily. These are some of the symptoms of a heart attack. Subscribe to our newsletter for the latest ...
If you have hypertrophic cardiomyopathy (HCM) and are experiencing symptoms such as shortness of breath, chest pain, ...
Beta blockers—drugs commonly prescribed for a range of cardiac conditions, including heart attacks—provide no clinical benefit for patients who have had an uncomplicated myocardial infarction with ...
In a new research trial, beta-blockers didnt appear to offer meaningful benefit to heart attack survivors with preserved heart function. A sub-study within the same trial suggests that women ...
One way or another, beta blockers are always in the news. Take, for instance, Los Angeles Chargers Head Coach Jim Harbaugh, who revealed in October that he's part of a growing group of Americans who ...
Beta blockers have been shown to prolong survival in chronic heart failure. It is currently a matter of debate whether any β blocker is superior to the other in terms of improving symptoms, left ...
Propranolol, a beta-blocker commonly prescribed to treat irregular heart rates and other conditions, has significant anti-cancer properties, say researchers in a new clinical study published in ...
New experimental evidence supports the idea that future therapeutic strategies for treating cardiovascular disease could target sites within the brain. Our recent study demonstrates the existence of ...
Heart disease continues to rank as the leading cause of death in the Black community, claiming thousands of lives annually. While lifestyle modifications remain foundational to heart health, modern ...
When someone survives a heart attack, their recovery journey often includes a small pharmacy of medications—each serving a specific purpose in their healing process and long-term protection.